Curative efficacy and safety of Epirubicin in combination with Capecitabine in treatment of triple-negative breast cancer
- VernacularTitle:表柔比星联合卡培他滨治疗三阴性乳腺癌的疗效及安全性分析
- Author:
Li LUO
;
Dongxin TANG
;
Dingxue WANG
;
Jinghui WANG
;
Lulu JIN
;
Bin YANG
- Publication Type:Journal Article
- Keywords:
Epirubicin;
Capecitabine;
triple-negative breast cancer;
vascular endothelial growth factor C
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(9):138-140
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate curative efficacy and safety of Epirubicin in combination with Capecitabine in the treatment of triple-negative breast cancer and its effects on level of serum vascular endothelial growth factor C ( VEGF-C).Methods 86 patients of triple-negative breast cancer who received therapy from January 2013 to December 2014 were selected as research objects.According to therapeutic schemes,those patients were divided into control group(n=42)and observation group(n=44).Control group was treated with epirubicin,while observation group was treated with Epirubicin in combination with Capecitabine.Then, the short-term curative efficacy, adverse events effects,level of VEGF-C were observed and compared.Results After the course of treatment, the short-term curative efficacy ratio in control group and observation group was 59.5% and 65.9% respectively with no statistical difference.During the treatment, the occurrence of neutropenia, hand-foot syndrome, gastrointestinal reaction, cardiac damage and liver function damage in the two groups was statistically same respectively.After post-treatment, in comparison with control group, level of VEGF-C in observation group was statistically lower ( P <0.05 ).Conclusion Epirubicin in combination with Capecitabine is effective for triple-negative breast cancer,which has high short-term curative efficacy ratio and significantly decrease level of VEGF-C with not increasing occurrence of toxic side effects.
